Results 261 to 270 of about 15,549,143 (355)

Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control. [PDF]

open access: yesNat Metab
Chilloux J   +39 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Adipose Tissue in SARS‐CoV‐2 Viral Tropism, Viral Replication, and the Concept of a Viral Reservoir: An Update

open access: yesObesity, EarlyView.
Adipose tissue as a potential reservoir for and modifier of SARS‐CoV‐2 infection and its complications. Schematic demonstrating the differences in subcutaneous and visceral adipose tissue and infection capacity of SARS‐CoV‐2 with interplay between macrophages and adipocytes as target cells for viral tropism.
Liam Charles Maher   +2 more
wiley   +1 more source

Freestyle Libre-Derived Metrics in Assessing Glycemic Control in Diabetic Dogs. [PDF]

open access: yesJ Vet Intern Med
Del Baldo F   +6 more
europepmc   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesObesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella   +9 more
wiley   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

open access: yesObesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays   +9 more
wiley   +1 more source

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT‐1 Trial

open access: yesObesity, EarlyView.
ABSTRACT Objective This prespecified subpopulation analysis aimed to assess the efficacy and safety of once‐weekly tirzepatide versus placebo alongside lifestyle intervention in Japanese adults with obesity or overweight. Methods Data from 102 Japanese adults in the SURMOUNT‐1 trial with BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 and ≥ 1 weight‐related comorbidity ...
Yasushi Ishigaki   +4 more
wiley   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

open access: yes
The Laryngoscope, EarlyView.
Alina Zgardau   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy